Neurodegenerative Diseases

R&D

The ALS clinical trial landscape is characterised by a significant number of active trials and sponsors, including MediciNova's Ph3 with MN-166.

News

The FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.

News

Roche has scrapped two drugs for Huntington's disease – tominersen and RG6496 – after seeing disappointing results in clinical trials.

News

Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.

News

Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle in a phase 2b trial.

News

Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.